INO vs. ELMD, PROF, INGN, BWAY, LAKE, DRTS, LNSR, CATX, SKIN, and PDEX
Should you be buying Inovio Pharmaceuticals stock or one of its competitors? The main competitors of Inovio Pharmaceuticals include Electromed (ELMD), Profound Medical (PROF), Inogen (INGN), BrainsWay (BWAY), Lakeland Industries (LAKE), Alpha Tau Medical (DRTS), LENSAR (LNSR), Perspective Therapeutics (CATX), Beauty Health (SKIN), and Pro-Dex (PDEX). These companies are all part of the "medical equipment" industry.
Inovio Pharmaceuticals vs.
Electromed (NYSE:ELMD) and Inovio Pharmaceuticals (NASDAQ:INO) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, community ranking, profitability, dividends, valuation, analyst recommendations, earnings and media sentiment.
Electromed has a beta of 0.41, indicating that its share price is 59% less volatile than the S&P 500. Comparatively, Inovio Pharmaceuticals has a beta of 0.92, indicating that its share price is 8% less volatile than the S&P 500.
In the previous week, Inovio Pharmaceuticals had 17 more articles in the media than Electromed. MarketBeat recorded 20 mentions for Inovio Pharmaceuticals and 3 mentions for Electromed. Inovio Pharmaceuticals' average media sentiment score of 0.47 beat Electromed's score of 0.30 indicating that Inovio Pharmaceuticals is being referred to more favorably in the news media.
Electromed has a net margin of 11.34% compared to Inovio Pharmaceuticals' net margin of 0.00%. Electromed's return on equity of 15.71% beat Inovio Pharmaceuticals' return on equity.
Electromed has higher revenue and earnings than Inovio Pharmaceuticals. Inovio Pharmaceuticals is trading at a lower price-to-earnings ratio than Electromed, indicating that it is currently the more affordable of the two stocks.
Electromed presently has a consensus price target of $38.00, suggesting a potential upside of 57.61%. Inovio Pharmaceuticals has a consensus price target of $12.20, suggesting a potential upside of 574.03%. Given Inovio Pharmaceuticals' higher possible upside, analysts plainly believe Inovio Pharmaceuticals is more favorable than Electromed.
Inovio Pharmaceuticals received 699 more outperform votes than Electromed when rated by MarketBeat users. However, 91.30% of users gave Electromed an outperform vote while only 70.94% of users gave Inovio Pharmaceuticals an outperform vote.
40.8% of Electromed shares are owned by institutional investors. Comparatively, 26.8% of Inovio Pharmaceuticals shares are owned by institutional investors. 14.0% of Electromed shares are owned by company insiders. Comparatively, 2.5% of Inovio Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Summary
Electromed beats Inovio Pharmaceuticals on 12 of the 19 factors compared between the two stocks.
Get Inovio Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for INO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Inovio Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:INO) was last updated on 3/26/2025 by MarketBeat.com Staff
